Comment on CMS-2026-1256-0002
AdvaMedOpposeAdvocacy
Summary: The Advanced Medical Technology Association (AdvaMed) opposes CMS's proposal to repeal the alternative New Technology Add-on Payment (NTAP) and Transitional Pass-Through (TPT) pathways for FDA-designated Breakthrough Devices. They argue that these pathways are essential for ensuring timely patient access to innovative technologies and that the proposed repeal would impose an undue burden on manufacturers and disrupt the medical technology pipeline.
AdvaMed is pleased to submit comments regarding the New Technology Add-On Pathway proposals in the FY 2027 IPPS Proposed Rule. Please see attached for our comment letter. Thank you for the opportunity to comment.